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ABSTRACT
Chemokines mediate immune cell trafficking during tissue
development, wound healing and infection. The chemokine CCL2
is best known to regulate macrophage recruitment during wound
healing, infection and inflammatory diseases. While the importance
of CCL2/CCR2 signaling in macrophages during cancer
progression is well documented, we recently showed that CCL2-
mediated breast cancer progression depends on CCR2 expression
in carcinoma cells. Using 3DMatrigel: Collagen cultures of SUM225
and DCIS.com breast cancer cells, this study characterized the
mechanisms of CCL2/CCR2 signaling in cell growth and invasion.
SUM225 cells, which expressed lower levels of CCR2 than
DCIS.com cells, formed symmetrical spheroids in Matrigel:
Collagen, and were not responsive to CCL2 treatment. DCIS.com
cells formed asymmetric cell clusters in Matrigel: Collagen. CCL2
treatment increased growth, decreased expression of E-cadherin
and increased TWIST1 expression. CCR2 overexpression in
SUM225 cells increased responsiveness to CCL2 treatment,
enhancing growth and invasion. These phenotypes corresponded
to increased expression of Aldehyde Dehydrogenase 1A1
(ALDH1A1) and decreased expression of the mitochondrial serine
protease HTRA2. CCR2 deficiency in DCIS.com cells inhibited
CCL2-mediated growth and invasion, corresponding to decreased
ALDH1A1 expression and increased HTRA2 expression. ALDH1A1
and HTRA2 expression were modulated in CCR2-deficient
and CCR2-overexpressing cell lines. We found that ALDH1A1 and
HTRA2 regulates CCR2-mediated breast cancer cell growth and
cellular invasion in a CCL2/CCR2 context-dependent manner. These
data provide novel insight on the mechanisms of chemokine signaling
in breast cancer cell growth and invasion, with important implications
on targeted therapeutics for anti-cancer treatment.
This article has an associated First Person interview with the first
author of the paper.
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INTRODUCTION
Chemokines are small soluble proteins (8 kda) that regulate cellular
homing and recruitment to tissues through formation of concentration
gradients. They are highly conserved among mammals, and mediate
immune cell trafficking and angiogenesis during tissue development,
wound healing and infection (Proost et al., 2017; Rees et al., 2015;
Ridiandries et al., 2016). More than 50 chemokine ligands and 25
chemokine receptors have been identified, and are categorized into
several classes depending on the composition of a conserved cysteine
motif at the N terminus: C-C, C-X-C and CX3C, in which the X is a
non-cysteine amino acid residue (Borroni et al., 2018; Lacalle et al.,
2017; Yao et al., 2016a). CCL2 (MCP-1) belongs to the C-C class
of chemokines, and is a critical regulator of macrophage recruitment
during wound healing, infection and chronic inflammatory diseases
such as rheumatoid arthritis (De Paepe et al., 2008; Koelink et al.,
2009). While CCL2 is capable of binding multiple receptors, it binds
with highest affinity to CCR2 (Bonini and Steiner, 1997; Monteclaro
and Charo, 1996). CCL2/CCR2 signaling in macrophages leads to
increased chemotaxis and cellular adhesion through activation of
G proteins and signaling through p42/44MAPK, Phospho-Lipase C
gamma and Protein Kinase C pathways (Ashida et al., 2001). Mice
exhibiting knockout of CCL2 or CCR2 show defects in macrophage
recruitment during bacterial infection, macular degeneration or
autoimmune encephalitis (Boring et al., 1997; Huang et al., 2001;
Kurihara et al., 1997). The lack of compensatory upregulation of
chemokine ligands or receptors indicates unique biological functions
for CCL2/CCR2 signaling during inflammation.
CCL2 and CCR2 expression are chronically overexpressed in
multiple cancer types including: glioblastoma, prostate, colon and
breast cancer (Baier et al., 2005; Chavey et al., 2007; Leung et al.,
1997; Tsaur et al., 2015). In breast cancer patients, elevated levels of
CCL2 have been detected in blood serum (Lebrecht et al., 2004).
Furthermore, increased CCL2 protein expression in breast tumor
tissues are associated with macrophage levels, and correlate with
tumor grade and poor patient prognosis (Fujimoto et al., 2009; Saji
et al., 2001; Ueno et al., 2000; Yao et al., 2016b). In animal models
of breast cancer, stable expression of CCL2 shRNAs in breast tumor
xenografts or treatment of primary tumors with CCL2 neutralizing
antibodies leads to decreased primary tumor growth and systemic
metastasis, correlating with decreased recruitment of M2 polarized
macrophages to tissues (Fujimoto et al., 2009; Hembruff et al.,
2010; Qian et al., 2011). These studies demonstrate that CCL2
promotes breast cancer progression in part through recruitment of
macrophages to the primary tumor.
While the importance of CCL2/CCR2 signaling in macrophages
during cancer progression is well documented, we recently showed
that CCL2-mediated breast cancer progression depends on CCR2
expression in carcinoma cells. By immunostaining, CCR2 protein
was found to be overexpressed in breast carcinoma tissues, and
datamining analysis revealed that RNA levels correlated withReceived 7 December 2018; Accepted 22 May 2019
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decreased distant metastasis free survival (Brummer et al., 2018;
Fang et al., 2012). Flow cytometry analysis of breast cancer cell
lines demonstrated that CCR2 protein expression correlated with
invasive potential (Fang et al., 2012). In particular, highly invasive
DCIS.com breast cancer cells expressed higher levels of CCR2 than
lowly invasive SUM225 cells. shRNA knockdown of CCR2 in
DCIS.com breast cancer cells inhibited formation of invasive breast
carcinomas in animal models. CCR2 overexpression in SUM225
breast cancer cells enhanced formation of breast carcinomas
(Brummer et al., 2018). These studies have demonstrated a unique
role for CCR2 expression in epithelial cells in regulating invasive
progression of breast carcinomas. Yet, the mechanisms through
CCL2/CCR2 signaling in epithelial cells facilitate these disease
processes remain poorly understood.
Using 3DMatrigel: Collagen cultures of SUM225 and DCIS.com
breast cancer cells, this study characterized the mechanisms
through which CCL2/CCR2 signaling regulated cell growth and
invasion. SUM225 cells formed symmetrical spheroids in Matrigel:
Collagen, were lowly invasive, and were not responsive to CCL2
recombinant protein. DCIS.com cells formed asymmetric cell
clusters in Matrigel: Collagen. CCL2 treatment increased growth
and increased expression of TWIST, a mesenchymal marker
and decreased expression of E-cadherin, an epithelial marker.
CCR2 overexpression in SUM225 cells increased responsiveness to
CCL2 treatment, resulting in increased growth, cellular invasion
and increased expression of TWIST and decreased expression of
E-cadherin. These pro-tumorigenic phenotypes corresponded
to increased expression of Aldehyde Dehydrogenase 1A1
(ALDH1A1), and decreased expression of the mitochondrial
serine protease HTRA2. CRISPR knockout or shRNA knockdown
of CCR2 in DCIS.com cells inhibited CCL2-mediated growth, EMT
and invasion, corresponding to decreased ALDHA1 expression and
increased HTRA2 expression. We modulated ALDH1A1 and
HTRA2 expression in CCR2 deficient and breast cancer cell lines
with induced or endogenous CCR2 overexpression. We found that
ALDH1A1 and HTRA2 regulates CCR2-mediated breast cancer cell
growth and cellular invasion in a CCL2/CCR2 context-dependent
manner. In summary, CCL2/CCR2 chemokine signaling regulates
breast cancer cell growth and invasion through increased ALDH1A1
expression and suppression of HTRA2. These data provide
novel insight in the mechanisms of chemokine signaling in breast
cancer cell growth and invasion, with important implications on
development of targeted therapeutics for anti-cancer treatment.
RESULTS
CCL2 enhances growth and invasion of DCIS.com but not
SUM225 cells
Tumor malignancy is characterized by loss of tissue-defining
structures, and can be modeled by 3D cultures (Debnath et al.,
2002; Herrmann et al., 2014; Krause et al., 2008; Li and Lu, 2011).
Normal or lowly invasive cells form symmetrical hollow spheroids,
while highly invasive cancer cells form asymmetrical cell clusters
with no discernable shape. To elucidate the mechanisms through
which CCL2/CCR2 signaling regulated breast cancer cell growth
and invasion, we first analyzed the effects of CCL2 treatment on
DCIS.com and SUM225 breast cancer cell growth and invasion in
3D Matrigel: Collagen cultures. SUM225 cells, which expressed
lower levels of CCR2 than DCIS.com cells (Brummer et al., 2018),
formed symmetrical spheroids in Matrigel: Collagen. Spheroid size
was not affected by CCL2 treatment at increasing concentrations
(Fig. 1A). As SUM225 cell clusters formed visible invasive
protrusions, the effects of CCL2 treatment on cellular invasion in
3D cultures were quantified. The invasion index (Cisneros Castillo
et al., 2016) was calculated by dividing total area by main body
area of each spheroid and subtracting from 1 (Fig. 1B). CCL2
treatment did not affect invasiveness of SUM225 cells in 3D cultures
(Fig. 1C). In contrast, DCIS.com cells formed asymmetrical cell
clusters, which spread out in Matrigel: Collagen. These cell clusters
significantly increased in size over time in response to CCL2
treatment, correlating with decreased E-cadherin expression, an
epithelial marker and increased TWIST1 expression, a mesenchymal
marker (Fig. 1D–E) (Soini et al., 2011; Zheng and Kang, 2014).
CCR2 expression is required for CCL2-mediated breast
cancer cell growth and invasion
We next determined whether increased CCR2 expression in
SUM225 cells would enhance responsiveness to CCL2 treatment.
Two cell lines were generated to overexpress CCR2, one showing
22.1% positive expressing cells (CCR2-L) and the second one
showing 41.5% positive expressing cells (CCR2-H), compared to
8.5% CCR2 positive in pHAGE vehicle control cells (Brummer
et al., 2018). Compared to pHAGE control cells, CCR2-L and
CCR2-H cultured alone did not show changes in spheroid size in
Matrigel: Collagen (Fig. 2A). However, CCR2-H cells cultured
alone showed a higher invasion index, compared to pHAGE and
CCR2-L cells (Fig. 2B), and was associated with higher CCL2
levels compared to pHAGE control (Fig. S1). CCL2 treatment at
100 ng/ml, but not 60 ng/ml, further enhanced spheroid size and
increased the invasion index of CCR-H cells. As a complementary
approach, cellular invasion was quantified by Matrigel transwell
invasion assay. Similarly to 3D cultures, 100 ng/ml CCL2 enhanced
transwell invasion of CCR2-H cells (Fig. S2). In contrast to 3D
cultures, we noted that untreated CCR2-H cells did not show
changes in transwell invasion, possibly reflecting differences in
matrix interactions in a 3D environment versus a monolayer with
SUM225 cells. Overall, these data indicate that CCL2 treatment of
CCR2-H cells increased spheroid size and invasiveness in a dose-
dependent manner.
To determine whether CCL2/CCR2-mediated changes in
spheroid size and invasion were related to cell proliferation,
survival and EMT, immunofluorescence staining was performed on
3D cultures. CCR2 overexpression and CCL2 treatment of
SUM225 cells did not affect cleaved caspase-3 expression
(Fig. S3), indicating no changes in apoptosis (Parton et al., 2002).
100 ng/ml CCL2 treatment of CCR2-H cells increased expression of
PCNA (Fig. 2C), a cell proliferation marker (van Dierendonck et al.,
1991). CCR2-H cells showed a partial decrease in E-cadherin
expression, which was further decreased with 100 ng/ml CCL2
treatment (Fig. 2D). CCR2-H cells showed increased TWIST1
expression when treated with 60 ng/ml or 100 ng/ml CCL2
(Fig. 2E). Interestingly, 100 ng/ml CCL2 treatment of pHAGE and
CCR2-L cells increased PCNA expression, although increased
PCNA levels were not sufficient to significantly affect overall
spheroid size in these groups. pHAGE and CCR2-L still expressed
CCR2 but in a smaller percentage of cells than CCR2-H cells
(Brummer et al., 2018). It is possible that CCR2 expression in
pHAGE and CCR2-L cells enabled responsiveness to CCL2 and
increased PCNA staining (Fig. 2C), but was not sufficient enough to
contribute to spheroid growth over time. Alternatively, the cell cycle
of SUM225 cells could have been so slow such that the increase in
PCNA expression would not be reflected in an immediate increase in
spheroid size. In summary, these data indicate that increased CCL2/
CCR2 signaling in SUM225 breast cancer cells promotes cell
proliferation, and invasion associated with increased TWIST1 and
2
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decreased E-cadherin. Given that CCR2-H but not CCR2-L cells
showed changes in cellular phenotype, these data indicate that
levels of CCR2 expression in SUM225 cells determine CCL2
responsiveness.
To further the significance of CCR2 expression to breast
cancer cell growth and invasion, we induced CCR2 expression in
established 3D cultures. TAT cell penetrating peptides form
non-covalent crosslinks to plasmid DNA in the presence of
CaCl2. These complexes form nanoparticles that efficiently
penetrate cells and tissues to modulate gene expression (Baoum
et al., 2012, 2009). SUM225 cells were first cultured in Matrigel:
Collagen for 2 days, and then transfected with TAT cell penetrating
peptides complexed to a vehicle control plasmid (Ca-TAT/pHAGE)
or CCR2 overexpression plasmid (Ca-TAT/CCR2). Delivery of
Ca-TAT/CCR2 complexes, but not Ca-TAT/pHAGE controls,
visibly increased CCR2 expression in SUM225 cells (Fig. S4A).
Induction of CCR2 expression increased spheroid size over time
(Fig. S4B), which was associated with increased cellular invasion,
not cell proliferation (Fig. S4C,D). These data are consistent
with the phenotypes observed with SUM225 CCR2-H cells.
In summary, these data indicate that CCR2 overexpression
in established SUM225 spheroid cultures enhances breast cancer
cell invasion.
As a complementary approach, we examined the effects of
CCR2 deficiency on DCIS.com growth and invasion. In previous
studies, we had ablated CCR2 gene expression in DCIS.com
cells by CRISPR (CCR2-KO), which inhibited formation of
invasive ductal carcinomas (Brummer et al., 2018). In wild-type
(WT) DCIS.com cells, 35.1% of cells were positive for CCR2
expression. 12.3% of cells in CCR2-KO cells were CCR2 positive
(Brummer et al., 2018). In 3D cultures, CCR2 knockout alone did
not affect the size of DCIS.com cell clusters but inhibited CCL2
induction of cell growth (Fig. 3A). As invasion index was difficult
to assess with the asymmetric cell cluster formation of DCIS.com
cells in 3D cultures; invasion was quantified by transwell assay.
CCR2 knockout alone did not significantly affect transwell
Fig. 1. Responsiveness of SUM225 and
DCIS.com breast cancer cells to CCL2
treatment in 3D cultures. (A–C) SUM225 breast
cancer cells were cultured in Matrigel: Collagen,
in the presence or absence of recombinant CCL2
(60 or 100 ng/ml), and analyzed for changes in
spheroid size over time for up to 10 days.
Representative images of spheroids at day 10
are shown with magnified inset. Spheroid size
was measured using ImageJ (A). Invasion index
was calculated by dividing total area by main
body area of each spheroid and subtracting from
1 (B). Invasion index was determined for
SUM225 3D cultures in the presence or absence
of CCL2 treatment (C). Spheroid size and
invasion index were normalized to spheroid
number. Mean number of spheroids analyzed
per group±s.e.m: untreated, 170±58; 60 ng/ml
CCL2, 159±35; 100 ng/ml CCL2, 183±32.
(D,E) DCIS.com cells were embedded in
Matrigel: Collagen, treated with 60 ng/ml CCL2,
and analyzed for growth over time for up to
10 days (D). Representative images of
asymmetric cell clusters are shown with
magnified inset. 3D cell culture sections were
immunostained for expression of E-Cadherin or
TWIST1, with DAPI counterstain at day 10 (E).
Experimental groups were plated in triplicate and
experiments were performed three times. Two
slides containing three sections each were
subject to immunostaining. Mean number of
spheroids analyzed per group±s.e.m.: untreated,
267±34; CCL2, 239±54. Statistical analysis was
performed using two-tailed t-test (D) or one-way
ANOVA with Bonferroni post-hoc comparison
(A,C). **P<0.01; n.s, not significant. Scale bars:
100 µm. Mean±s.e.m. is shown.
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invasion, but inhibited CCL2-mediated invasion (Fig. 3B).
Biomarker staining analysis indicated that CCR2-KO inhibited
CCL2 induction of PCNA expression in WT DCIS.com cells
(Fig. 3C). Cleaved caspase-3 expression was not affected
by CCR2-KO or CCL2 treatment (Fig. 3D). These data indicate
that CCL2 enhances DCIS.com cell proliferation but not apoptosis
in a CCR2-dependent manner. Analysis of EMTmarkers indicated
that CCL2 inhibited E-cadherin expression inWT cells. CCR2-KO
prevented CCL2 suppression of E-cadherin expression (Fig. 3E).
CCL2 increased TWIST1 expression in WT cells, which was
inhibited with CCR2-KO (Fig. 3F). In summary, these data
indicate that CCL2/CCR2 signaling enhances DCIS.com cell
proliferation and invasion associated with increased TWIST1 and
decreased E-cadherin.
To validate the effects of CCR2-KO, we examined DCIS.com
cells that stably expressed CCR2 shRNAs (CCR2-KD). Compared
to cells expressing control shRNAs, CCR2-KD cells showed a 50%
decrease in CCR2 expression, compared to cells expressing
control shRNAs, corresponding to decreased formation of
invasive ductal carcinomas in mice (Brummer et al., 2018).
CCR2-KD inhibited CCL2-mediated cell growth and invasion
(Fig. S5A,B), associated with decreased PCNA expression, but there
were no changes in Cleaved Caspase-3 expression (Fig. S5C,D).
CCL2 inhibited E-cadherin expression in control cells. CCR2-KD
prevented CCL2 suppression of E-Cadherin expression (Fig. S5E).
CCR2-KD suppressed CCL2-mediated TWIST1 expression in
DCIS.com cells (Fig. S5F). These phenotypes are similar to
CRISPR gene ablation of CCR2.
Fig. 2. CCR2 overexpression in SUM225
breast cancer cells enhances growth
and invasion. (A,B) pHAGE control or
CCR2-overexpressing SUM225 cells
(CCR2-L, CCR2-H) were cultured in 3D
Matrigel: Collagen for up to 10 days, and
measured for (A) spheroid size and
(B) invasion index. Spheroid size and
invasion index were normalized to spheroid
number. (C–E) SUM225 cultures were
immunofluorescence stained for (C) PCNA,
(D) E-Cadherin or (E) TWIST1 expression.
Expression was quantified by ImageJ, and
normalized to DAPI. Experimental groups
were plated in triplicate and experiments
were performed three times. Two slides
containing three sections each were
subject to immunostaining. Mean number
of spheroids analyzed per group±s.e.m.:
pHAGE untreated, 143±12; pHAGE+60 ng/ml
CCL2, 196±23; pHAGE+100 ng/ml CCL2,
172±12; CCR2-L untreated, 161±27;
CCR2-L+60 ng/ml CCL2, 165±23; CCR2-
L+100 ng/ml CCL2, 220±16; CCR2-H
untreated, 138±29; CCR2-H+60 ng/ml
CCL2, 132±5; CCR2-H+100 ng/ml CCL2,
158±21. Statistical analysis was performed
using one-way ANOVA with Bonferroni
post-hoc comparison. *P<0.05, **P<0.01,
***P<0.001; n.s, not significant. Scale bars:
100 µm. Mean±s.e.m. is shown.
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CCL2/CCR2-mediatedbreast cancercell growthand invasion
are associated with increased ALDH1A1 and decreased
HTRA2 expression
To determine the molecular mechanisms through which CCL2/
CCR2 signaling regulates breast cancer cell growth and invasion,
we examined for expression of downstream factors. ALDH1A1 is a
metabolic enzyme that functions as a pro-invasive factor and stem
cell marker (Ginestier et al., 2007; Sapudom et al., 2015), and
positively corresponded to CCR2 expression in breast carcinomas
(Brummer et al., 2018). In 3D cultures, CCR2 overexpression alone
in SUM225 cells (CCR2-L and CCR2-H) did not affect ALDH1A1
expression or activity compared to pHAGE control cells. CCL2
treatment of CCR2-H cells enhanced ALDH1A1 expression and
activity, compared to pHAGE or CCR2-L cells treated with CCL2
(Fig. 4A,B). In DCIS.com WT cells, CCL2 increased ALDH1A1
expression and activity, which was inhibited with CCR2-KO
(Fig. 4C,D). Similarly, CCL2 increased ALDH1A1 expression and
activity in DCIS.com expressing control shRNA cells which were
significantly decreased with CCR2-KD (Fig. 4E,F). These data
indicate that CCL2/CCR2 signaling positively regulates ALDH1A1
expression and activity in breast cancer cells.
Previous studies showed that HTRA2, a pro-apoptotic
mitochondrial serine protease (Xu et al., 2012) inversely
corresponded to CCR2 expression in breast cancer (Brummer et al.,
2018). In SUM225 cells, CCR2 overexpression alone (CCR2-L,
CCR2-H) did not significantly affect HTRA2 expression (Fig. 5A).
CCL2 treatment at 60 ng/ml and 100 ng/ml significantly
decreased HTRA2 expression in CCR2-H, but not CCLR2-L or
pHAGE control cells. In DCIS.com cells, CCL2 treatment
decreased HTRA2 expression in WT and control shRNA
expressing cells. CCR2-KO or CCR2-KD prevented CCL2
suppression of HTRA2 expression (Fig. 5B,C). These data
Fig. 3. CRISPR gene ablation of CCR2 in
DCIS.com cells inhibits growth and invasion.
(A) DCIS.com cells expressing wild-type CCR2
(WT) or CRISPR knocked out for CCR2 (CCR2-
KO) were embedded in Matrigel: Collagen for up to
10 days and analyzed for changes in spheroid
size. (B) DCIS.com cells were treated with
60 ng/ml CCL2 and invasion was assessed by
Matrigel transwell assay for 24 h. (C–F) DCIS.com
3D cultures were analyzed for expression of PCNA
(C), Cleaved Caspase-3 (D), E-cadherin (E) or
TWIST1 (F) with DAPI counterstain. Spheroid size
was normalized to spheroid number. Expression
was quantified by ImageJ, and normalized to
DAPI. Experimental groups were plated in
triplicate. Experiments were performed three times.
Two slides containing three sections each were
subject to immunostaining. Mean number of
spheroids analyzed per group±s.e.m.: WT
untreated, 194±12; WT±CCL2, 188±19; CCR2-KO
untreated, 195±67; CCR2-KO±CCL2, 268±21.
Data are representative of four experiments.
Statistical analysis was performed using one-way
ANOVA with Bonferroni post-hoc comparison.
*P<0.05, **P<0.01; n.s, not significant. Scale bars:
100 µm. Mean+s.e.m. is shown.
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indicate that CCL2/CCR2 signaling negatively regulates HTRA2
expression in breast cancer cells.
ALDH1A1 positively regulates CCR2-mediated breast cancer
cell growth and invasion in a CCL2/CCR2 context-dependent
manner
We modulated ALDH1A1 expression in CCR2-overexpressing and
CCR2-deficient cells to determine its contribution to CCL2/CCR2-
mediated growth and invasion. As CCL2 treatment enhanced
ALDH1A1 expression and activity in CCR2-H SUM225 cells,
ALDH1A1 was knocked down in these cells through stable shRNA
expression. In CCR2-H cell lines expressing two different targeting
shRNAs reduced ALDH1A1 expression to 36% (ALDH-KD#1)
and to 26.8% (ALDH-KD#5) relative to levels detected in control
cells (Fig. 6A). ALDH1A1 knockdown did not significantly affect
HTRA2 expression. ALDH1-KD#1 did not show changes in
spheroid size or invasiveness. ALDH-KD#5 cells showed a 20%
decrease in spheroid size associated with decreased cell
proliferation, but not invasion or changes in E-cadherin or
TWIST1 expression in 3D cultures (Fig. 6B–D, Figs S6 and S7A,B).
These data indicate an association between the level of ALDH1A1
knockdown to effects on cell proliferation in CCR2-overexpressing
SUM225 cells. We examined the role of ALDH1A1 in DCIS.com
cells. CCR2-deficient DCIS.com cells inhibited CCL2-
induced ALDH1A1 expression. Therefore, ALDH1A1 was stably
overexpressed in CCR2-KO DCIS.com cells through lentiviral
transduction (Fig. 6E). ALDH1A1 overexpression did not
significantly affect HTRA2 expression. Compared to DCIS.com
CCR2-KO cells transduced with pHAGE control lentivirus,
ALDH1A1 overexpression increased spheroid size in 3D cultures,
associated with increased cell proliferation but not cellular invasion,
or changes to E-cadherin or TWIST1 expression (Fig. 6F–H,
Fig. 4. CCR2 positively regulates
ALDH1A1 expression in SUM225
and DCIS.com breast cancer cells.
(A,B) 3D cultures of pHAGE, CCR2-L or
CCR2-H SUM225 cells were treated with
or without 60 or 100 ng/ml CCL2 and
analyzed for ALDH1A1 expression by
immunofluorescence staining (A) or activity
by Aldered assay (B). (C,D) 3D cultures of
WT or CCR2-KO DCIS.com breast cancer
cells were treated with or without 60 ng/ml
CCL2 and analyzed for ALDH1A1
expression by immunofluorescence
staining (C) or activity by Aldered assay (D).
(E,F) 3D cultures of control (Con) or
CCR2-KD DCIS.com cells were treated
with or without 60 ng/ml CCL2 and
analyzed for ALDH1A1 expression by
immunofluorescence staining (E) or activity
by Aldered assay (F). Expression was
quantified by ImageJ, and normalized to
DAPI. Experimental groups were plated in
triplicate and repeated three times. Two
slides containing three sections each
were subject to immunostaining. Statistical
analysis was performed using one-way
ANOVA with Bonferroni post-hoc
comparison. *P<0.05, ***P<0.001. Scale
bars: 100 µm. Mean+s.e.m. is shown.
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Fig. S7C,D). In summary, these data indicate that ALDH1A1 is
important for CCL2/CCR2-mediated breast cancer cell growth,
but not invasion.
To examine how ALDH1A1 functioned in a breast cancer cell
line with high levels of endogenous CCR2, we knocked
down ALDH1A1 by stable shRNA expression in parental
DCIS.com cells. In ALDH1A1-KD#1 cells, ALDH1A1 was
knocked down to 52.3% relative to control cells. In ALDH1A1-
KD#5 cells, ALDH11A1 was decreased to 6% relative to
control cells. (Fig. 7A). ALDH1A1 knockdown did not affect
HTRA2 expression. ALDH1-KD#1 and ALDH1-KD#5 showed
a significant decrease in CCL2-induced DCIS.com spheroid
growth in 3D cultures, associated with decreased PCNA
expression (Fig. 7B,C). ALDH1A1 knockdown did not affect
basal level spheroid growth or PCNA expression. By transwell
assay, ALDH1-KD#5 did not affect basal level DCIS.com
invasion, but inhibited CCL2-induced invasion (Fig. 7D).
ALDH1A1 knockdown resulted in a small but not statistically
significant increase in E-cadherin expression in CCL2-treated
cells (Fig. 7E) and significantly inhibited CCL2-induced
TWIST1 expression (Fig. 7F). In summary, these data indicate
that in parental DCIS.com cells, ALDH1A1 regulates
CCL2-induced growth and invasion.
HTRA2 negatively regulates CCR2-mediated breast cancer
cell growth and invasion in a CCL2/CCR2 context-dependent
manner
We then modulated HTRA2 expression in CCR2-overexpressing
and CCR2-deficient cells to determine its contribution to CCL2/
CCR2-mediated growth and invasion. As CCR2 overexpression in
SUM225 cells decreased HTRA2 expression, HTRA2 expression
was rescued through lentiviral transduction of CCR2-H cells.
Interestingly, HTRA2 rescue significantly decreased ALDH1A1
expression by 28.3% in CCR2-H SUM225 cells (Fig. 8A).
HTRA2 overexpression inhibited spheroid size, associated with
decreased cell proliferation and invasion of CCR2-H cells,
associated with decreased TWIST1 and increased E-cadherin
expression (Fig. 8B–D, Figs S8 and S9A-B). As a complementary
approach, HTRA2 expression was knocked down in CCR2-KO
DCIS.com cells through shRNA expression. Relative to control
cells, HTRA2 expression was decreased to 55.5% in HTRA2-KD#2
cells, and decreased to 66.9% in HTRA2-KD#3 cells (Fig. 8E).
ALDH1A1 expression was not significantly affected with HTRA2
knockdown in CCR2-KO DCIS.com cells. CCR2-KO cells
expressing HTRA2-KD#2 but not HTRA2-KD#3 shRNAs
showed a significant increase in spheroid size associated with
increased cell proliferation (Fig. 8F,G). HTRA2-KD#2 and
Fig. 5. CCR2 negatively regulates HTRA2
expression in SUM225 and DCIS.com
breast cancer cells. (A) 3D cultures of
pHAGE, CCR2-L or CCR2-H SUM225 cells
were treated with or without 60 or 100 ng/ml
CCL2 and analyzed for HTRA2 expression
by immunofluorescence staining. (B,C) WT
or CCR2-KO DCIS.com cells (B), Con
shRNA or CCR2-KD DCIS.com cells (C)
were cultured in 3D matrices in the
presence of absence of 100 ng/ml CCL2
and analyzed for HTRA2 expression by
immunofluorescence staining. Expression
was quantified by ImageJ and normalized
to DAPI. Experimental groups were plated
in triplicate and experiments were
performed three times. Two slides
containing three sections each were subject
to immunostaining. Statistical analysis was
performed using one-way ANOVA with
Bonferroni post-hoc comparison. *P<0.05,
***P<0.001; n.s, not significant. Scale bars:
100 µm. Mean+s.e.m. is shown.
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HTRA2-KD#3 did not show significant changes in cellular
invasion, E-cadherin or TWIST1 expression (Fig. 8H, Fig. S9C,D).
In summary, these data indicate that HTRA2 suppresses CCR2-
mediated cell proliferation in SUM225 and DCIS.com cells, and
suppresses invasion of CCR2-overexpressing SUM225 cells, but not
DCIS.com cells.
To examine how HTRA2 functioned in a breast cancer cell
line with high levels of endogenous CCR2, we overexpressed
HTRA2 in parental DCIS.com cells. DCIS.com cells showed
robust HTRA2 overexpression, which did not significantly
affect ALDH1A1 expression (Fig. 9A). HTRA2 overexpression
inhibited basal level and CCL2-induced DCIS.com spheroid
growth in 3D cultures, associated with decreased PCNA expression
(Fig. 9B,C). By transwell assay, HTRA2 overexpression did
not affect basal level DCIS.com invasion, but did inhibit CCL2-
induced invasion (Fig. 9D), associated with increased E-cadherin
expression and decreased TWIST1 expression (Fig. 9E,F)
In summary, these data indicate that in parental DCIS.com
cells, HTRA2 negatively regulates CCL2-induced growth
and invasion.
Associations between p42/44MAPKand SMAD3 activity with
CCL2-mediated ALDH1A1 and HTRA2 expression in
DCIS.com and CCR2-overexpressing SUM225 cells
In previous studies, we demonstrated an important role for p42/
44MAPK and SMAD3 in CCL2/CCR2 breast cancer cell motility
(Fang et al., 2012). Compared to pHAGEvehicle control and parental
DCIS.com cells, CCR2-H SUM225 cells showed higher levels of
phospho-p42/44MAPK and total p42/44MAPK expression. Parental
DCIS.com cells showed higher levels of phospho-SMAD3 and
SMAD3 protein compared to pHAGE or CCR2-SUM225 cells
(Fig. 10A). To determine the relevance of p42/44MAPK and
SMAD3 to ALDH1A1 and HTRA2 expression, we knocked down
expression of p42/44MAPK or SMAD3 by siRNA transfection in
DCIS.com and CCR2-H SUM225 cells, treated with or without
CCL2 and examined for ALDH1A1 and HTRA2 expression by
Fig. 6. ALDH1A1 overexpression or knockdown
affects CCR2-H SUM225 and CCR2-KO
DCIS.com breast cancer cell growth but not
invasion. (A–D) CCR2-H SUM225 cells
expressing Con shRNAs or shRNAs to ALDH1A1
(ALDH-KD#1, ALDH-KD#5) were analyzed for
ALDH1A1 and HTRA2 expression by immunoblot
(A), spheroid size in 3D cultures (B), PCNA
expression (C) or invasion index (D). Mean
number of spheroids analyzed per group±s.e.m.:
Con, 197±18; ALDH-KD#1, 190±10; ALDH-KD#5,
196±87. (E–H) CCR2-KO DCIS.com cells
expressing vehicle control (pHAGE) or ALDH1A1
(ALDH-OE) were analyzed for: expression of
ALDH1A1 and HTRA2 by immunoblot (E),
spheroid size in 3D cultures (F), PCNA expression
(G) or transwell invasion (H). Protein levels in
immunoblots were measured by densitometry.
Expression levels were normalized to control
group. Representative blots of three experiments
are shown. Spheroid size and invasion index were
normalized to spheroid number. Experimental
groups were plated in triplicate. Experiments were
performed three times. Two slides containing three
sections each were subject to immunostaining.
Mean number of spheroids analyzed per group
±s.e.m.: pHAGE, 275±58; ALDH-OE, 219±38.
Statistical analysis was performed using one-way
ANOVA with Bonferroni post-hoc comparison.
*P<0.05; n.s, not significant. Mean±s.e.m. is
shown.
8









 by guest on November 17, 2020http://bio.biologists.org/Downloaded from 
immunoblot. In DCIS.com cells, p42/44MAPK and SMAD3
knockdown inhibited ALDH1A1 expression in CCL2-treated and
untreated cells, and increased HTRA2 expression in CCL2-treated
and untreated cells. In CCR2-H SUM225 cells, p42/44MAPK and
SMAD3 knockdown did not affect ALDH1A1 expression in
untreated cells, but inhibited CCL2 induced ALDH1A1 expression.
p42/44MAPK and SMAD3 knockdown did not visibly affect
HTRA2 expression in untreated or CCL2-treated cells (Fig. 10B).
These data indicate that p42/44MAPK and SMAD3 signaling
pathways positive regulate CCL2-mediated ALDH1A1 and
negatively regulate HTRA2 expression in DCIS.com cells. In
CCR2-H SUM225 cells, p42/44MAPK and SMAD3 positively
regulate ALDH1A1 expression, and do not affect HTRA2
expression. In summary, these data indicate differences in
intracellular signaling in DCIS.com and CCR2-overexpressing
SUM225 cells that influence ALDH1A1 and HTRA2 expression.
DISCUSSION
Recent studies have shown that CCL2/CCR2 chemokine signaling
in carcinoma cells enhances breast cancer growth and invasion
(Brummer et al., 2018). However, the mechanisms through which
CCL2/CCR2 signaling promotes cancer progression are poorly
understood. Using 3D cell culture and transwell invasion systems,
we report that CCL2/CCR2 signaling regulates breast cancer cell
growth and invasion in part by enhancing ALDH1A1 expression
and suppressing HTRA2 expression. However, the contributions of
ALDH1A1 and HTRA2 to breast cancer cell growth and invasion
may depend on a complex set of factors involving differences in
CCL2/CCR2 signaling among breast cancer cell lines.
CCL2/CCR2-mediated breast cancer progression was associated
with increased growth, invasion and decreased tumor cell apoptosis
(Brummer et al., 2018). Here, we found that CCL2/CCR2 signaling
in DCIS.com and SUM225 cells in 3D cultures enhanced
Fig. 7. ALDH1A1 knockdown inhibits
DCIS.com breast cancer cell growth and
invasion. (A–F) DCIS.com cells expressing
control shRNAs (Con) or shRNAs to
ALDH1A1 (ALDH-KD#1, ALDH-KD#5)
were treated with/without 100 ng/ml CCL2
and analyzed for (A) ALDH1A1 and HTRA2
expression by immunoblot, (B) spheroid
size in 3D cultures, (C) PCNA expression,
(D) transwell invasion, (E) E-cadherin or
(F) TWIST1 expression. Mean number of
spheroids analyzed per group±s.e.m.: Con,
163+9; Con+CCL2, 165+7; ALDH-KD#1
152+12; ALDH-KD#1+CCL2, 168+11;
ALDH-KD#5, 174+10; ALDH-KD#5+CCL2,
162+13. Protein levels in immunoblots
were measured by densitometry.
Expression levels were normalized to
control group. Representative blots of three
experiments are shown. Spheroid size
and invasion index were normalized to
spheroid number. Experimental groups
were plated in triplicate. Experiments
were performed three times. Two slides
containing three sections each were subject
to immunostaining. Statistical analysis was
performed using one-way ANOVA with
Bonferroni post-hoc comparison. *P<0.05,
**P<0.01; n.s, not significant. Mean±s.e.m.
is shown.
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proliferation and invasion, but had no effect on apoptosis. It is
possible that differences in 3D cultures and tissues may account
for differences towards apoptosis. For one, 3D cultures lacked
stromal components that may affect breast cancer cell survival.
CCR2 overexpression in breast lesions was associated with
accumulation of fibroblasts (Brummer et al., 2018). In addition to
CCL2, fibroblasts secrete other pro-survival factors such as HGF
and TGF-β (Soriano et al., 1998). These factors act directly on breast
cancer cells to inhibit programmed cell death (Zhang et al., 2017). In
addition, TGF-β promote tumor cell survival by suppressing CD8+
T cell function, differentiate pro-inflammatory T cell populations
and enhance polarization of myeloid cells to a wound-healing
phenotype (Dahmani and Delisle, 2018; Fridlender et al., 2009;
Gratchev, 2017). While there are some limitations to 3D culture
systems, our studies indicate that some tumor phenotypes such as
cell growth and invasion are reproduced in vitro.
While CCL2 is expressed in carcinoma cells, studies have
indicated that CCL2 expression in the stroma is a more significant
prognostic indicator in breast cancer (Fujimoto et al., 2009; Yao et al.,
2016b). Furthermore, CCL2 derived from fibroblasts is important for
enhancing breast tumor growth, invasion and metastasis (Brummer
et al., 2018; Hembruff et al., 2010). These data suggest that paracrine
CCL2 signaling to breast cancer cells is an important mechanism for
CCR2-mediated breast cancer progression. Here, CCL2 stimulation
of CCR2 overexpressing cells enhanced growth and invasion more
than CCR2 overexpression alone, further supporting an important
role for paracrine CCL2/CCR2 signaling to breast cancer cells.
Interestingly, CCR2 overexpression alone in SUM225 cells enhanced
invasion associated with increased CCL2 expression and p42/
44MAPK signaling, indicating that breast cancer cell invasion may
also be regulated in part by autocrine CCL2/CCR2 signaling
mechanisms, characterized in part by p42/44MAPK activity. In
addition to p42/44MAPK, CCL2/CCR2 activates multiple signaling
pathways in breast cancer cells including: PKC, Rho and SRC to
regulate growth and motility (Fang et al., 2012). These pathways are
also important in breast cancer cell invasion (Gautam et al., 2018;
Fig. 8. HTRA2 overexpression or knockdown
affects CCR2-H SUM225 and CCR2-KO
DCIS.com breast cancer cell growth and
invasion. (A–D) CCR2-H SUM225 cells
expressing vehicle control (pHAGE) or HTRA2
(HTRA2-OE) were analyzed for HTRA2
expression by immunoblot (A), spheroid size in
3D cultures (B), PCNA expression (C) or invasion
index (D). Mean number of spheroids analyzed
per group±s.e.m.: pHAGE, 269±63; HTRA2-OE,
227±28. (E–H) CCR2-KO DCIS.com cells were
transduced with lentivirus expressing Con or
HTRA2 shRNAs (HTRA2-KD#2, HTRA2-KD#3)
and analyzed for HTRA2 expression by
immunoblot (E), spheroid size in Matrigel:
Collagen (F), PCNA expression (G) or transwell
invasion (H). Spheroid size and invasion index
were normalized to spheroid number.
Experimental groups were plated in triplicate.
Experiments were repeated three times. Two
slides containing three sections each were
subject to immunostaining. Mean number of
spheroids analyzed/group±s.e.m.: Con, 196±80;
HTRA2-KD#2, 219±99; HTRA2-KD#2, 161±40.
Statistical analysis was performed using two-
tailed t-test (A–D) or one-way ANOVA with
Bonferroni post-hoc comparison (E–H). *P<0.05,
**P<0.01, ***P<0.001; n.s, not significant.
Mean±s.e.m. is shown.
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Kim et al., 2017; Matsuura et al., 2010; Shi et al., 2017). It would be
of interest in the future to distinguishwhich pathways are mediated by
paracrine versus autocrine CCL2/CCR2 signaling in breast cancer
cells to regulate cell growth and invasion.
In previous studies of animal models, we showed that CCR2
expression positively regulated breast carcinoma growth and
invasion (Brummer et al., 2018; Yao et al., 2019). Here, we
observed that CCR2 overexpression and CCR2 deficiency in breast
cancer cells resulted in some complementary phenotypes. CCL2
treatment of CCR2-overexpressing SUM225 cells enhanced
spheroid growth and cell invasion, associated with increased
ALDH1A1 and decreased HTRA2 expression. Conversely, CCR2
knockdown or knockout in DCIS.com cells inhibited CCL2-
induced: spheroid growth, cell invasion and ALDH1A1 expression,
and prevented CCL2 suppression of HTRA2 expression. Changes
in cellular invasion were accompanied by consistent changes in
E-cadherin and TWIST1 expression. However, some conflicting
phenotypes were observed. CCR2 overexpression alone in SUM225
cells was sufficient to enhance invasion. Yet, CCR2 deficiency in
DCIS.com cells alone did not show differences in invasion. These
studies suggest that other oncogenic pathways may be involved in
malignancy of DCIS.com cells. Pathways such as TGF-β or IL-8
regulate EMT and invasion (Bhowmick et al., 2001; Zhang et al.,
2016), and may compensate for loss of CCR2 expression to sustain
invasion in more tumorigenic cell lines, such as DCIS.com. It
is also possible that CCR2 may coordinate growth and invasion in
DCIS.com cells with other oncogenes that are not present in
SUM225 cells. G Protein Coupled Receptors crosstalk with receptor
tyrosine kinases such as EGFR (Wang, 2016), which are
overexpressed in breast cancers (Sainsbury et al., 1987; Toi et al.,
1991). In future studies, it would be of interest to examine how
CCR2 coordinates breast tumor growth and invasion with other
oncogenic factors.
Here, we found that CCL2 treatment combined with CCR2
overexpression significantly enhanced ALDH1A1 expression and
activity in CCR2-H SUM225 and DCIS.com cells. ALDH1A1 is a
highly conserved enzyme dehydrogenase in alcohol metabolism,
and functions to convert acetaldehyde to acetate (Koppaka et al.,
Fig. 9. HTRA2 overexpression inhibits
DCIS.com breast cancer cell growth and
invasion. (A–F) DCIS.com cells expressing
pHAGE control or HTRA2 were analyzed
for (A) ALDH1A1 and HTRA2 expression
by immunoblot, (B) spheroid size in 3D
cultures, (C) PCNA expression,
(D) transwell invasion, (E) E-cadherin or
(F) TWIST1 expression. Mean number of
spheroids analyzed per group±s.e.m.:
pHAGE, 325±25; pHAGE±CCL2, 358±33;
HTRA2-OE, 343±17; HTRA2-OE±CCL2,
316±44. Protein levels in immunoblots were
measured by densitometry. Expression
levels were normalized to control group.
Representative blots of three experiments
are shown. Spheroid size and invasion
index were normalized to spheroid number.
Experimental groups were plated in
triplicate. Experiments were performed
three times. Two slides containing three
sections each were subject to
immunostaining. Statistical analysis was
performed using two-tailed t-test (A) or
one-way ANOVA with Bonferroni post-hoc
comparison (B–F). *P<0.05, **P<0.01,
***P<0.001; n.s, not significant.
Mean±s.e.m. is shown.
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2012; Smith et al., 2015), and converts all trans- and 9 cis-
retinaldehydes to retinoic acid (RA) (Fan et al., 2003; Paterson et al.,
2013) during melanogenesis and retina development.
ALDH1A1 expression and activity have been implicated in tumor
cell proliferation, cancer stem cell renewal, invasion and drug
resistance (Charafe-Jauffret et al., 2010; Ginestier et al., 2007;
Rodriguez-Torres and Allan, 2016; Xu et al., 2015). We noted that
WT control cells showed greater ALDH1A1 expression and activity
with CCL2 treatment compared to control shRNA expressing cells.
The differences in ALDH1A1 and Aldered activity could be due to
inherent genetic or epigenetic differences when shRNA expressing
cells and CRISP/R knockout cells were generated. CCR2 shRNAs
were expressed in a heterogenous pool of DCIS.com cells.
CCR2-KO was generated through clonal selection during the
CRISPR process (Brummer et al., 2018). Despite the differences in
how these cells were generated, CCR2 shRNA knockdown and
CRISPR knockout both led to a reduction in breast cancer survival
and invasion in animal models (Brummer et al., 2018). Here, CCL2
treatment enhanced ALDH1A1 expression and Aldered activity in
both control cell lines, which were inhibited by CCR2 shRNA or
CRISP/R knockout.
Altering ALDH1A1 expression in CCR2-H SUM225, CCR2-KO
and parental DCIS.com cells led to changes in spheroid size
and PCNA expression, indicating that an important role for
ALDH1A1 in breast cancer cell growth regardless of cell line or
CCR2 status. The exact molecular mechanisms through which
ALDH1A1 selectively regulates growth in breast cancer cells is
unclear, but could involve FOXM1 and Notch signaling.
ALDH1A1 activates FOXM1 and Notch1 to promote ovarian
tumorigenesis and stemness (Young et al., 2015). FOXM1 and
Notch1 regulate expression of cell cycle and metabolic genes in
cancer (Sanchez-Martin and Ferrando, 2017; Wierstra and Alves,
2007; Yao et al., 2018). Alternatively, ALDH1A1 conversion of
retinaldehydes to RA could serve to enhance breast cancer
proliferation. RA exerts its biological effects by activating nuclear
receptors PPAR β/δ and facilitating RA Receptor (RAR) and
Retinoid X Receptor (RXR) complexes to response elements for
gene transcription (Schug et al., 2007; Singh et al., 2015). RA
activity can promote growth of pancreatic cancers or inhibit colon
cancer growth (Balasubramanian et al., 2004; Mollersen et al.,
2004). RAR and RXR have been implicated in pro-apoptotic and
suppression of cell growth (Schug et al., 2007). Yet, RA can also
activate pathways involved in cell proliferation and stem cell activity
including p42/44MAPK (Yen et al., 1998), PKC (Wu et al., 2017)
and p38MAPK (Alsayed et al., 2001). Alternatively, ALDH1A1
may have other substrates that are involved in breast cancer cell
growth, which could be identified through a broad high-throughput
substrate screen. In summary, it is possible that ALDH1A1
expression and activity in DCIS.com and SUM225 CCR2-
overexpressing breast cancer cells may facilitate cell growth
through metabolites that activate oncogenic pathways.
Interestingly, we noticed differences in the effects of modulating
ALDH1A1 expression in parental DCIS.com, CCR2-H SUM225
and CCR2-KO DCIS.com cell invasion. In CCR2-KO DCIS.com
cells, ALDH1A1 overexpression did not rescue invasion. This
may be because these cells lacked other components required
for cellular invasion. For example, CCR2 deficiency in DCIS.com
cells inhibited TWIST1 expression. TWIST1 expression regulates
expression of genes associated with cellular adhesion, cell motility
and actin cytoskeletal reorganization (Mikheeva et al., 2010). It is
possible that CCR2-KO of DCIS.com cells inhibited one or more of
these critical factors, and therefore, ALDH1A1 overexpression by
itself was not sufficient to restore invasion. In CCR2-H SUM225
cells, ALDH1A1 knockdown did not affect invasion. However, in
parental DCIS.com cells, ALDH1A1 knockdown inhibited CCL2
induced cellular invasion. The contributions of ALDH1A1 to
invasion of CCR2-H SUM225 versus parental DCIS.com cells may
due to differences in intracellular signaling. CCR2-H SUM225
showed increased p42/44MAPK while DCIS.com cells showed
higher levels of SMAD3 signaling, which could regulate invasion of
genes associated with invasion or modulate changes in actin
cytoskeletal reorganization that works with ALDH1A1 to regulate
invasion. In addition, DCIS.com cells showed increased RAS
overexpression (Miller et al., 2000). In pancreatic cancer, RAS-
Fig. 10. Effect of p42/44MAPK and SMAD3
knockdown on CCL2/CCR2-mediated
ALDH1A1 and HTRA2 expression.
(A) DCIS.com, pHAGE or CCR2-H SUM225
cell lines were analyzed for expression of the
indicated proteins by immunoblot. Arrow points
to SMAD3 protein approximately 50 kda in size.
(B) DCIS.com or CCR2-H SUM225 cells were
transfected with control siRNAs or siRNAs to
p42/44MAPK or SMAD3, stimulated with CCL2
for 24 h and analyzed for expression of the
indicated proteins by immunoblot.
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mediated invasion and motility was associated with increased
ALDH1A1 expression (Rachagani et al., 2011). In DCIS.com cells,
RAS may drive ALDH1A1 expression, which activate NOTCH1 to
enhance EMT and invasion (Shao et al., 2015; Young et al., 2015).
It is possible that the differences in RAS expression may contribute
to how ALDH1A1 functions in CCR2-H SUM225 cells versus
parental DCIS.com cells.
Our studies indicate that HTRA2 is important in CCL2/CCR2-
mediated breast cancer cell growth and invasion, but not apoptosis.
HTRA2 is best known for its role as an apoptotic inducer through
binding and cleaving inhibitors of apoptosis proteins (Guo et al.,
2016; Kilbride and Prehn, 2013). A few studies have indicated that
HTRA2may have other cellular functions. Mice exhibiting knockout
of HTRA2 (Omi) do not show changes in cell death in tissues
(Martins et al., 2004). Another study has shown that HTRA2
suppresses cell proliferation through binding to WARTS (WTS)/
large tumor-suppressor 1 mitotic kinase (Kuninaka et al., 2007).
HTRA2 cleaves STAT3 protein to modulate expression of cytokines
that regulate T cell proliferation (Lee et al., 2016). These studies
indicate that HTRA2 cleaves multiple substrates, including proteins
that directly regulate the cell cycle, or indirectly, through modulating
activity of transcription factors involved in cell proliferation. HTRA2
may function downstream of CCL2/CCR2 to regulate cell
proliferation and invasion through similar mechanisms.
Modulating HTRA2 expression in CCR2-H SUM225, CCR2-KO
and parental DCIS.com cells led to changes in spheroid size and
PCNA expression, indicating that HTRA2 exerts important effects on
breast cancer cell growth regardless of cell line or CCR2 status. Yet,
modulating HTRA2 expression affected breast cancer cell invasion
differently among the three cell lines. HTRA2 overexpression in
CCR2-H SUM225 cells decreased cell invasion, indicating that
CCR2-mediated SUM225 cellular invasion is directly associated
with HTRA2 expression. In CCR2 deficient DCIS.com cells,
HTRA2 knockdown did not restore cellular invasion, suggesting
that CCR2 deficiency inhibits expression or activity of other
components required for cellular invasion such as TWIST1.
HTRA2 overexpression in parental DCIS.com cells alone led to a
small decrease in invasion and significantly inhibited CCL2-induced
invasion, suggesting that CCL2-stimulated invasion is dependent on
suppression of HTRA2 expression. In mouse embryonic fibroblasts
and NIH3T3 deficient for p53, RAS transforms cells and promotes
cellular invasion by preventing HTRA2-mediated cleavage of beta
actin, enabling phosphorylating p130Cas to promote formation of
integrin adhesion complexes and lamellipodia (Yamauchi et al.,
2014). In parental DCIS.com cells, a similar mechanismmay occur in
which CCL2-mediated RAS activity may prevent HTRA2-mediated
cleavage of beta actin. In addition, RAS activates signaling pathways
including p42/44MAPK, which negatively regulated HTRA2
expression in DCIS.com cells. RAS also regulates PI3kinase, AKT
and PKC pathways, all of which modulate activity of transcription
factors (Bos, 2018), and may also suppress HTRA2 expression in
DCIS.com cells.
In CCR2-H SUM225 cells, HTRA2 overexpression decreased
ALDH1A1 expression, while HTRA2 knockdown in CCR2-KO
DCIS.com cells and HTRA2 overexpression in parental cells did
not affect ALDH1A1 expression. In SUM225 cells, CCR2
overexpression may enhance mechanisms that couple HTRA2 to
ALDH1A1 expression. Proteomics profiling of Jurkat T cells
identified HTRA2 substrates including: ALDH isoforms as
substrates (Vande Walle et al., 2007). Alternatively, HTRA2
cleaves co-factors such as E2F1 (Ma et al., 2015) that interact with
NF-Y to regulate ALDH1A1 promoter activity (van Ginkel et al.,
1997; Yanagawa et al., 1995). It is possible that CCR2overexpression
decreased HTRA2 expression to stabilize ALDH1A1 protein levels
or gene expression. In contrast, for CCR2-KO and parental
DCIS.com cells, HTRA2 and ALDH1A1 could function
independently of each other, or multiple pathways regulate HTRA2
and ALDH1A1 expression. As such, modulating HTRA2 or
ALDH1A1 expression would not affect expression of the other gene.
Interestingly, CCR2 overexpression in SUM225 cells resulted in
some differences in p42/44MAPK and SMAD3 expression and
activity compared to DCIS.com cells. p42/44MAPK and SMAD3
positively regulated ALDH1A1 expression and negatively regulated
HTRA2 expression in CCL2-treated DCIS.com cells. SMAD3 and
p42/44MAPK positively regulated CCL2-induced ALDH1A1
expression and did not affect HTRA2 expression in CCR2-H
SUM225 cells. These differences in intracellular signaling, and
regulation of ALDH1A1 and HTRA2 expression could dictate how
CCL2/CCR2 regulates cell growth, invasion in CCR2-H SUM225
cells and DCIS.com cells. The mechanisms responsible for these
differences in intracellular signaling are unclear, but could in part
relate to differences in mechanisms that control p42/44MAPK and
SMAD3 expression and activity in DCIS.com cells and SUM225
cells. p42/44MAPK is regulated by a number of negative and
positive feedback mechanisms. Ras GAP protein regulates Ras
activation of Raf, MEK and subsequently p42/44MAPK (Hennig
et al., 2016). One mechanism is Kinase Suppressor of Ras proteins,
which act as a scaffold for p42/44MAPK pathway and regulate
localization of p42/44MAPK to Raf-1 (Frodyma et al., 2017).
SMAD3 gene expression is regulated by the TGF-β pathway (Zhao
and Geverd, 2002). SMAD binding proteins such as SnoN, SKI and
Protein Kinase B/AKT regulate SMAD3 activity and sequestration
to the cyotoplasm (Conery et al., 2004). It would be interest in the
future to understand how CCR2 regulates growth, invasion,
ALDH1A1 and HTRA2 expression and activity in different cell
lines through examination of other signal transduction pathways.
In summary, this study demonstrates that CCL2/CCR2
chemokine signaling in breast cancer cells is an important
regulatory mechanism for cell growth and invasion. CCL2 and
CCR2 are currently therapeutic targets of interest for anti-cancer
treatment and inflammatory diseases (Bertrand and Tardif, 2017;
Lim et al., 2016). Patients diagnosed with invasive or metastatic
breast cancer have a more unfavorable prognosis than patients with
non-invasive disease (DeSantis et al., 2017). By understanding the
molecular and cellular mechanisms of CCL2/CCR2 signaling
facilitating growth and invasion of cancer cells, we may better
understand the potential effects of CCL2 or CCR2 inhibitors on




DCIS.com and SUM225 breast cancer cells were kindly provided by Dr
Fariba Behbod (University of Kansas Medical Center). SUM225 cells were
maintained in Ham’s F-12 medium containing: 10% Fetal Bovine Serum
(FBS), 0.1% amphotericin and 0.1% penicillin-streptomycin. DCIS.com
cells were maintained in DMEM with 10% FBS/0.1% amphotericin/0.1%
penicillin-streptomycin. Cells were analyzed for mycoplasma after every
freeze/thaw using the MycoAlert™Mycoplasma Detection Kit (Lonza, cat.
no. LT07-318). Cells were maintained no longer than 3 months at a time.
Lentiviral transduction
The following plasmids were used to create cell lines: GIPZ ALDH1a1
shRNA, glycerol set (RHS4531-EG216): V2LHS_112035,V2LHS_112037,
V2LHS_112039, V2LHS_265598, V3LHS_398453, V3LHS_398455.
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GIPZ HTRA2 shRNA, glycerol set (RHS4531-EG27429): V3LHS_
315862, V3LHS_315863, V3LHS_315864, V3LHS_3155866.
MGC Human HTRA2 sequence-verified cDNA (3508944), MGC
Human ALDH1a1 sequence verified-cDNA (2988388). To generate
lentivirus, 293T cells were transduced 6 μg psPAX2, 3 μg pMD.2G and
10 μg of the plasmid of interest. The media was harvested twice a day for
3 days, and concentrated in 8.5% PEG 6000 and 0.4 M NaCl. Parental
DCIS.com, CCR2-KO DCIS.com and CCR2-H SUM225 were transduced
with lentivirus for 24 h before the media was replaced.
siRNA transfection
40,000 cells were seeded into 24-well plates for 24 h. 8 pmol of siRNAs to
control (Ambion, cat. no. AM4613), SMAD3 (Santa Cruz Biotechnology,
cat. no. sc-38376), p42MAPK (Santa Cruz Biotechnology cat. no.
sc-29307) mixed with p44MAPK (Santa Cruz Biotechnology, cat. no.
35335) were complexed at a 1:10 ratio to lipofectamine 2000
(Invitrogen cat. no. 11668027) and transfected into cells for 24 h in
DMEM. The media was replaced with DMEM/10% FBS for 24 h prior to
CCL2 stimulation.
3D cell culture
Cells were cultured in Collagen: Matrigel, using procedures adapted from
previous studies (Berens et al., 2015). Rat tail collagen (3.5 mg/ml)
(Corning, cat. no. 354236) was mixed at a 4:1 ratio with setting solution
comprised of: 1× EBSS, 75 mM NaOH and 290 mM NaHCO3. The
collagen solution was then diluted 1:1 with Growth Factor Reduced
Matrigel (BD Pharmingen, cat. no. 354230). 96-well plates were coated
with 40 µl/well of the Matrigel: Collagen solution for 30 min at 37°C.
Breast cancer cells (2500) were re-suspended in 200 µl growth medium
containing 2.5% Matrigel and seeded in each well for 24 h. Cells were
treated with or without recombinant human CCL2 (Peprotech, cat. no.
300-04) at 60 ng/ml or 100 ng/ml. Cells were cultured for up to 10 days,
with the medium changed at day 4 and 8. Images were captured every
2 days using the EVOS FL Auto Imaging System (Invitrogen) at 10×
magnification, four fields per well.
Immunofluorescence
Immunofluorescence staining of 3D cultures was adapted from previous
studies (Artym and Matsumoto, 2010). 3D culture spheroids were fixed in
10% neutral buffered formalin overnight at 4°C. Samples were removed
from 96-well plates and embedded in 4% agarose plugs. Samples were
dehydrated in 70, 90, 100% ethanols for 1 h each, and embedded in
paraffin blocks. 5 µm sections were de-waxed. To detect E-cadherin,
sections were permeabilized in PBS/0.1%TritonX-100 for 10 min, blocked
with PBS/3% FBS, incubated at 1:100 with E-cadherin antibodies (BD
Pharmingen, cat. no. 610181) overnight. Sections were then incubated
with donkey anti-rabbit-AlexaFluor-647 (Invitrogen, cat. no. A-31573) at a
1:250 dilution for 2 h. For all other antigens, de-waxed sections were
subject to antigen retrieval by heating in 10 mM Sodium Citrate, pH 6.0
for 2 min at low pressure in a pressure cooker. Sections were
permeabilized in PBS containing 10% Methanol for 10 min. Slides were
blocked in PBS/3% FBS, and incubated overnight with antibodies (1:100)
to: Cleaved Caspase-3 (Cell Signaling Technology, cat. no. 9661S), or
TWIST1 (Santa Cruz Biotechnology, cat. no. sc.81417), PCNA
(BioLegend, cat. no. 307902), HTRA2 (Cell Signaling Technology, cat.
no. 2176S) or ALDH1A1 (RnD system, cat. no. MAB5869). Slides were
washed in PBS. PCNA was detected with donkey anti-rabbit-AlexaFluor-
647. Cleaved caspase-3 and HTRA2 were detected with biotinylated rabbit
antibodies (Vector Laboratories, cat. no. BA1000), followed by
AlexaFlour-568 conjugated streptavidin (Vector Laboratories, cat. no.
PK-4000). ALDH1A1 and TWIST1 was detected with biotinylated mouse
antibodies (Vector Laboratories, cat. no. BA9200), followed by Alexa-
Fluor-568 conjugated to streptavidin. Slides were counterstained with
DAPI, and mounted with 1:1 PBS: glycerol. Six random fields per sample
were captured at 10× magnification using the EVOS FL Auto Imaging
System. Antibody specificity was controlled through shRNA knockdown
and overexpression analysis by immunoblot, peptide competition assay
and omission of primary antibody staining, Expression was quantified by
ImageJ, using approaches described previously (Cheng et al., 2008).
Expression was normalized to DAPI.
Aldered assay
9 days after culture in Matrigel: Collagen, cells were subject to Aldered
ALDH detection assay (Millipore, cat. no. SCR150). Aldered-588 reagent
was prepared in assay buffer containing Verapamil to prevent efflux,
according tomanufacturer’s instructions. 5 µl of Aldered solution was added
to each with or without DEAB for 60 min at 37°C. Cells were counterstained
with DAPI. Fpur images per field at 10× magnification were captured using
the FL Auto EVOS Imaging system. Expression was quantified by ImageJ,
using approaches described previously (Cheng et al., 2008). Expression was
normalized to DAPI.
Quantitation of spheroid size and invasion
Images were opened in ImageJ. The total size was measured by outlining the
size of each cell cluster, adjusting with threshold analysis and analyzed for
total area. Pixel units were converted to microns (1 pixel2=1.125 µm2). The
invasion index was calculated as described in previous studies (Cisneros
Castillo et al., 2016). The main spheroid body (spheroid minus invasive
protrusions) was outlined, and measured for area. The invasion index was
calculated by dividing total area by main body area of each spheroid and
subtracting from 1.
Ca-TAT transfection
TAT peptides [sequence N to C: (+)H-RKKRRQRRR-NH2(+)] were
synthesized to purity >95% by Biomatik (Cambridge, Canada). Ca-TAT/
siRNA complexes were prepared at N/P 5 ratio using a formula adapted from
previous studies (Baoum et al., 2012). 1.41 µg TAT peptides were mixed
with 6 µg pHAGE–CMV-MCS-IRES-zsgreen control plasmids or pHAGE
plasmid carrying full length CCR2 cDNA (Brummer et al., 2018) in 45 µl
sterile de-ionized water containing 75 mMCaCl2. The solution was pipetted
20 times and incubated on ice for 20 min. These complexes were added to
3D cultures 2 days after cells were seeded.
Immunoblot
Cellswere lysed in buffercontaining: 10 mMTris-HCl, pH8.0, 0.1 mMEDTA,
0.1% sodium deoxycholate, 0.1% SDS and 140 mM NaCl with protease and
phosphatase inhibitors (Sigma-Aldrich, cat. no. P8340). 25 μg of protein were
resolved by 10% SDS-PAGE, transferred to nitrocellulose membranes and
probed with antibodies diluted 1:1000 to: ALDH1A1 (RnD system, cat. no.
MAB5869), HTRA2 (Cell Signaling Technology, cat. no. 2176S), β-actin
(Sigma-Aldrich, cat no. A5441), phospho-p42/44MAPK Thr202/Tyr204 (Cell
Signaling Technology, cat. no. 4376), p42/44MAPK (Cell Signaling
Technology, cat. no. 9102), phospho-SMAD3 Ser-423/425 (Cell Signaling
Technology, cat. no. 9520), SMAD3 (Cell Signaling Technology, cat. no.
9523). ALDH1A1 and β-actin were detected with mouse secondary antibodies
conjugated to horseradishperoxidase (HRP).HTRA2, phospho-p42/44MAPK,
p42/44MAPK, phospho-SMAD3 and SMAD3 were detected with anti-rabbit-
hrp. Membranes were developed with West Pico ECL substrate. Chemi-
luminescence signals were captured using UVP Imaging System.
Transwell invasion assay
8 µm pore transwells sized to 24-well plates (Corning, cat. no. 3464), were
coated with Growth Factor Reduced Matrigel (BD Biosciences, cat. no.
356230) diluted 1/10 in PBS for 30 min at 37°C. 75,000 cells were re-
suspended in 200 µl of serum-free medium and plated on top of each
transwell. 400 µl of serum-free medium was pipetted at the bottom of each
well, in the presence or absence of recombinant CCL2 (Peprotech, cat. no.
300-04). Cells were incubated at 37°C for 24 h, fixed in 10% neutral
formalin buffer and stained with 0.1% Crystal Violet. Cells were removed
from topside of the transwell by cotton swab. Four images per well were
captured using an Motic AE31 inverted microscope at 10× magnification.
Cell number was quantified by ImageJ.
ELISA
40,000 cells were seeded per well in 24-well plates for 24 h. Cells were
incubated with 500 µl of complete media for 24 h. Conditioned mediumwas
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assayed for human CCL2 (Peprotech, cat. no. 900-K31) according to
commercial protocols. Reactions were stopped using 2 M HCl. Absorbance
was read at OD450 nm using a Biotek plate reader.
Statistical analysis
Samples were plated in triplicate per group. All experiments were performed
a minimum of three times. Data are expressed as mean±s.e.m. Statistical
analysis was performed on Graphpad Software, using two-tailed t-test for
two groups or one-way ANOVA with Bonferroni post-hoc analysis with
more than two groups. Significance was determined by *P<0.05, **P<0.01,
***P<0.0001; n.s, not significant or P>0.05.
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TWIST1 promotes invasion through mesenchymal change in human
glioblastoma. Mol. Cancer 9, 194. doi:10.1186/1476-4598-9-194
Miller, F. R., Santner, S. J., Tait, L. and Dawson, P. J. (2000). MCF10DCIS.com
xenograft model of human comedo ductal carcinoma in situ. J. Natl. Cancer Inst.
92, 1185-1186. doi:10.1093/jnci/92.14.1185a
Mollersen, L., Paulsen, J. E., Olstorn, H. B., Knutsen, H. K. and Alexander, J.
(2004). Dietary retinoic acid supplementation stimulates intestinal tumour formation
and growth in multiple intestinal neoplasia (Min)/+ mice. Carcinogenesis 25,
149-153. doi:10.1093/carcin/bgg176
Monteclaro, F. S. and Charo, I. F. (1996). The amino-terminal extracellular domain
of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers
chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor
activation. J. Biol. Chem. 271, 19084-19092. doi:10.1074/jbc.271.32.19084
Parton, M., Krajewski, S., Smith, I., Krajewska, M., Archer, C., Naito, M., Ahern,
R., Reed, J. and Dowsett, M. (2002). Coordinate expression of apoptosis-
associated proteins in human breast cancer before and during chemotherapy.
Clin. Cancer Res. 8, 2100-2108.
Paterson, E. K., Ho, H., Kapadia, R. and Ganesan, A. K. (2013). 9-cis retinoic acid
is the ALDH1A1 product that stimulates melanogenesis. Exp. Dermatol. 22,
202-209. doi:10.1111/exd.12099
Proost, P., Struyf, S., Van Damme, J., Fiten, P., Ugarte-Berzal, E. and
Opdenakker, G. (2017). Chemokine isoforms and processing in inflammation
and immunity. J. Autoimmun. 85, 45-57. doi:10.1016/j.jaut.2017.06.009
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser,
E. A., Snyder, L. A. and Pollard, J. W. (2011). CCL2 recruits inflammatory
monocytes to facilitate breast-tumour metastasis. Nature 475, 222-225. doi:10.
1038/nature10138
Rachagani, S., Senapati, S., Chakraborty, S., Ponnusamy, M. P., Kumar, S.,
Smith, L. M., Jain, M. and Batra, S. K. (2011). Activated KrasG(1)(2)D is
associated with invasion and metastasis of pancreatic cancer cells through
inhibition of E-cadherin. Br. J. Cancer 104, 1038-1048. doi:10.1038/bjc.2011.31
Rees, P. A., Greaves, N. S., Baguneid, M. and Bayat, A. (2015). Chemokines in
wound healing and as potential therapeutic targets for reducing cutaneous
scarring. Adv. Wound Care (New Rochelle) 4, 687-703. doi:10.1089/wound.2014.
0568
Ridiandries, A., Tan, J. T. M. and Bursill, C. A. (2016). The role of CC-chemokines
in the regulation of angiogenesis. Int. J. Mol. Sci. 17, 1856. doi:10.3390/
ijms17111856
Rodriguez-Torres, M. and Allan, A. L. (2016). Aldehyde dehydrogenase as a
marker and functional mediator of metastasis in solid tumors. Clin. Exp.
Metastasis 33, 97-113. doi:10.1007/s10585-015-9755-9
Sainsbury, J. R., Farndon, J. R., Needham, G. K., Malcolm, A. J. and Harris,
A. L. (1987). Epidermal-growth-factor receptor status as predictor of early
recurrence of and death from breast cancer. Lancet 1, 1398-1402. doi:10.1016/
S0140-6736(87)90593-9
Saji, H., Koike, M., Yamori, T., Saji, S., Seiki, M., Matsushima, K. and Toi, M.
(2001). Significant correlation of monocyte chemoattractant protein-1 expression
with neovascularization and progression of breast carcinoma. Cancer 92,
1085-1091. doi:10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.
0.CO;2-K
Sanchez-Martin, M. and Ferrando, A. (2017). The NOTCH1-MYC highway toward
T-cell acute lymphoblastic leukemia. Blood 129, 1124-1133. doi:10.1182/blood-
2016-09-692582
Sapudom, J., Rubner, S., Martin, S., Thoenes, S., Anderegg, U. and Pompe, T.
(2015). The interplay of fibronectin functionalization and TGF-beta1 presence on
fibroblast proliferation, differentiation and migration in 3D matrices. Biomater. Sci.
3, 1291-1301. doi:10.1039/C5BM00140D
Schug, T. T., Berry, D. C., Shaw, N. S., Travis, S. N. and Noy, N. (2007). Opposing
effects of retinoic acid on cell growth result from alternate activation of two different
nuclear receptors. Cell 129, 723-733. doi:10.1016/j.cell.2007.02.050
Shao, S., Zhao, X., Zhang, X., Luo, M., Zuo, X., Huang, S., Wang, Y., Gu, S. and
Zhao, X. (2015). Notch1 signaling regulates the epithelial-mesenchymal transition
and invasion of breast cancer in a Slug-dependent manner. Mol. Cancer 14, 28.
doi:10.1186/s12943-015-0295-3
Shi, Y., An, D., Liu, Y., Feng, Q., Fang, X., Pan, G. andWang, Q. (2017). Propoxur
enhances MMP-2 expression and the corresponding invasion of human breast
cancer cells via the ERK/Nrf2 signaling pathway. Oncotarget 8, 87107-87123.
doi:10.18632/oncotarget.19081
Singh, S., Arcaroli, J., Thompson, D. C., Messersmith, W. and Vasiliou, V.
(2015). Acetaldehyde and retinaldehyde-metabolizing enzymes in colon and
pancreatic cancers. Adv. Exp. Med. Biol. 815, 281-294. doi:10.1007/978-3-319-
09614-8_16
Smith, C., Gasparetto, M., Jordan, C., Pollyea, D. A. and Vasiliou, V. (2015). The
effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis.
Adv. Exp. Med. Biol. 815, 349-359. doi:10.1007/978-3-319-09614-8_20
Soini, Y., Tuhkanen, H., Sironen, R., Virtanen, I., Kataja, V., Auvinen, P.,
Mannermaa, A. and Kosma, V.-M. (2011). Transcription factors zeb1, twist and
snai1 in breast carcinoma. BMC Cancer 11, 73. doi:10.1186/1471-2407-11-73
Soriano, J. V., Pepper, M. S., Orci, L. and Montesano, R. (1998). Roles of
hepatocyte growth factor/scatter factor and transforming growth factor-beta1 in
mammary gland ductal morphogenesis. J. Mammary Gland Biol. Neoplasia 3,
133-150. doi:10.1023/A:1018790705727
Toi, M., Osaki, A., Yamada, H. and Toge, T. (1991). Epidermal growth factor
receptor expression as a prognostic indicator in breast cancer. Eur. J. Cancer 27,
977-980. doi:10.1016/0277-5379(91)90262-C
Tsaur, I., Noack, A., Makarevic, J., Oppermann, E., Waaga-Gasser, A. M.,
Gasser, M., Borgmann, H., Huesch, T., Gust, K. M., Reiter, M. et al. (2015).
CCL2 chemokine as a potential biomarker for prostate cancer: a pilot study.
Cancer Res. Treat. 47, 306-312. doi:10.4143/crt.2014.015
Ueno, T., Toi, M., Saji, H., Muta, M., Bando, H., Kuroi, K., Koike, M., Inadera, H.
and Matsushima, K. (2000). Significance of macrophage chemoattractant
protein-1 in macrophage recruitment, angiogenesis, and survival in human
breast cancer. Clin. Cancer Res. 6, 3282-3289.
van Dierendonck, J. H., Wijsman, J. H., Keijzer, R., van de Velde, C. J. and
Cornelisse, C. J. (1991). Cell-cycle-related staining patterns of anti-proliferating
cell nuclear antigenmonoclonal antibodies. Comparison with BrdUrd labeling and
Ki-67 staining. Am. J. Pathol. 138, 1165-1172.
16









 by guest on November 17, 2020http://bio.biologists.org/Downloaded from 
van Ginkel, P. R., Hsiao, K.-M., Schjerven, H. and Farnham, P. J. (1997). E2F-
mediated growth regulation requires transcription factor cooperation. J. Biol.
Chem. 272, 18367-18374. doi:10.1074/jbc.272.29.18367
Vande Walle, L., Van Damme, P., Lamkanfi, M., Saelens, X.,
Vandekerckhove, J., Gevaert, K. and Vandenabeele, P. (2007). Proteome-
wide identification of HtrA2/Omi substrates. J. Proteome Res. 6, 1006-1015.
doi:10.1021/pr060510d
Wang, Z. (2016). Transactivation of epidermal growth factor receptor by G protein-
coupled receptors: recent progress, challenges and future research. Int. J. Mol.
Sci. 17, 95. doi:10.3390/ijms17010095
Wierstra, I. and Alves, J. (2007). FOXM1, a typical proliferation-associated
transcription factor. Biol. Chem. 388, 1257-1274. doi:10.1515/BC.2007.159
Wu, M.-J., Kim, M. R., Chen, Y.-S., Yang, J.-Y. and Chang, C.-J. (2017). Retinoic
acid directs breast cancer cell state changes through regulation of TET2-PKCzeta
pathway. Oncogene 36, 3193-3206. doi:10.1038/onc.2016.467
Xu, Z., Chen, X., Peng, C., Liu, E., Li, Y., Li, C. and Niu, J. (2012). The expression
and clinical significance of Omi/Htra2 in hepatocellular carcinoma.
Hepatogastroenterology 60, 6-13. doi:10.5754/hge12524
Xu, L., Zhu, Y., An, H., Liu, Y., Lin, Z., Wang, G. and Xu, J. (2015). Clinical
significance of tumor-derived IL-1beta and IL-18 in localized renal cell carcinoma:
associations with recurrence and survival. Urol. Oncol. 33, 68.e9-68.16. doi:10.
1016/j.urolonc.2014.08.008
Yamauchi, S., Hou, Y. Y., Guo, A. K., Hirata, H., Nakajima, W., Yip, A. K., Yu, C.-
H., Harada, I., Chiam, K.-H., Sawada, Y. et al. (2014). p53-mediated activation of
the mitochondrial protease HtrA2/Omi prevents cell invasion. J. Cell Biol. 204,
1191-1207. doi:10.1083/jcb.201309107
Yanagawa, Y., Chen, J. C., Hsu, L. C. and Yoshida, A. (1995). The transcriptional
regulation of human aldehyde dehydrogenase I gene. The structural and
functional analysis of the promoter. J. Biol. Chem. 270, 17521-17527. doi:10.
1074/jbc.270.29.17521
Yao, M., Brummer, G., Acevedo, D. and Cheng, N. (2016a). Cytokine regulation of
metastasis and tumorigenicity. Adv. Cancer Res. 132, 265-367. doi:10.1016/bs.
acr.2016.05.005
Yao, M., Yu, E., Staggs, V., Fan, F. and Cheng, N. (2016b). Elevated expression of
chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast
cancers. Mod. Pathol. 29, 810-823. doi:10.1038/modpathol.2016.78
Yao, S., Fan, L. Y.-N. and Lam, E. W.-F. (2018). The FOXO3-FOXM1 axis: a key
cancer drug target and amodulator of cancer drug resistance.Semin. Cancer Biol.
50, 77-89. doi:10.1016/j.semcancer.2017.11.018
Yao, M., Fang, W., Smart, C., Hu, Q., Huang, S., Alvarez, N., Fields, P. and
Cheng, N. (2019). CCR2 chemokine receptors enhance growth and cell-cycle
progression of breast cancer cells through SRC and PKC activation. Mol. Cancer
Res. 17, 604-617. doi:10.1158/1541-7786.MCR-18-0750
Yen, A., Roberson, M. S., Varvayanis, S. and Lee, A. T. (1998). Retinoic acid
induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase
(ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell
differentiation and growth arrest. Cancer Res. 58, 3163-3172.
Young, M.-J., Wu, Y.-H., Chiu, W.-T., Weng, T.-Y., Huang, Y.-F. and Chou, C.-Y.
(2015). All-trans retinoic acid downregulates ALDH1-mediated stemness and
inhibits tumour formation in ovarian cancer cells. Carcinogenesis 36, 498-507.
doi:10.1093/carcin/bgv018
Zhang, R.-L., Peng, L.-X., Yang, J.-P., Zheng, L.-S., Xie, P., Wang, M.-Y.,
Huang, B.-J., Zhao, H.-R., Bao, Y.-X. and Qian, C.-N. (2016). IL-8 suppresses
E-cadherin expression in nasopharyngeal carcinoma cells by enhancing
E-cadherin promoter DNA methylation. Int. J. Oncol. 48, 207-214. doi:10.
3892/ijo.2015.3226
Zhang, Y., Alexander, P. B. and Wang, X.-F. (2017). TGF-beta family signaling in
the control of cell proliferation and survival. Cold Spring Harb. Perspect. Biol. 9,
a022145. doi:10.1101/cshperspect.a022145
Zhao, Y. and Geverd, D. A. (2002). Regulation of Smad3 expression in bleomycin-
inducedpulmonary fibrosis: a negative feedback loopofTGF-beta signaling.Biochem.
Biophys. Res. Commun. 294, 319-323. doi:10.1016/S0006-291X(02)00471-0
Zheng, H. and Kang, Y. (2014). Multilayer control of the EMT master regulators.
Oncogene 33, 1755-1763. doi:10.1038/onc.2013.128
17









 by guest on November 17, 2020http://bio.biologists.org/Downloaded from 
Figure S1.  Effect of CCR2 overexpression 
on CCL2 expression. Conditioned medium 
from pHAGE or CCR2-H SUM225 cells were 
analyzed for CCL2 expression by ELISA. 
Statistical analysis was performed by Two 
Tailed T-test. Statistical significance was 






































































Figure S2. CCL2 enhances transwell invasion of 
CCR2 overexpressing SUM225 cells.  phAGE 
control or CCR2 overexpressing SUM225 breast 
cancer cells were treated with 100 ng/ml CCL2 and 
analyzed for invasion through Matrigel coated 
transwells. Statistical analysis was performed using 
One Way ANOVA with Bonferroni post-hoc 
comparison. Statistical significance was determined 
by p<0.05. *p<0.05. Mean +SEM are shown. 
*
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Untreated CCL2






















Figure S3. CCR2 overexpression in SUM225 cells does 
not affect apoptosis. SUM225 spheroids were 
immunofluorescence stained for Cleaved caspase-3  
expression. Expression was quantified by Image J, and 
normalized to DAPI. Statistical analysis was performed 
using One Way ANOVA with Bonferroni post-hoc 
comparison. Statistical significance was determined by 
p<0.05. ns.=not significant. Scale bar=100 microns. 
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Figure S4. Ca-TAT mediated induction of CCR2 expression  enhances  growth 
ofSUM225 spheroids. SUM225 breast cancer cells spheroids were seed in 
Matrigel:Collagen. After 2 days, cells were transfected with Ca-TAT peptides complexed to 
pHAGE vehicle control or CCR2 overexpression plasmid, and cultured for up to an 
additional 5 days.  Cultures were analyzed by A. immunofluorescence staining for CCR2 
expression, B. spheroid size over time, C. Invasion index and D. PCNA expression by IF 
staining. Spheroid size and invasion index are normalized to sphere number. Expression 
was quantified by Image J, and normalized to DAPI/sphere. Mean number + SEM 
spheroids analyzed: Ca-TAT/pHAGE= 78+25, Ca-TAT/CCR2=79+18. Statistical analysis 
was performed using Two Tailed T-test. Statistical significance was determined by p<0.05. 
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Figure S5. Stable CCR2 shRNA expression in DCIS.com cells inhibits growth and 
invasion.  DCIS.com cells expressing Control (Con) CCR2 shRNAs (CCR2-KD) were 
treated with or without 60 ng/ml CCL2 and analyzed for A. growth in Matrigel: Collagen, B. 
transwell invasion, and expression of C. PCNA, D. Cleaved caspase-3, E. E-cadherin and 
F. TWIST1. Mean number of spheroids analyzed/group +SEM:  Con Untreated= 248+28, 
Con+CCL2=243+21, CCR2-KD Untreated=243+41, CCR2-KD+CCL2= 181+3. Expression 
was quantified by Image J, and normalized to DAPI. Statistical analysis was performed 
using One Way ANOVA with Bonferroni post-hoc comparison. Statistical significance was 
determined by p<0.05. Statistical significance was determined by p<0.05. 

























































































Figure S6.  Effect of ALDH1 knockdown in SUM225 
CCR2-H cells on transwell invasion. SUM225 CCR2-H 
cells stably expressing control shRNAs (Con) or ALDH1 
shRNAs (ALDH1-KD#1, ALDH1-KD#5) were analyzed for 
transwell invasion. Statistical analysis was performed 
using One Way ANOVA with Bonferroni post-hoc 
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Figure S7. Effect of ALDH1A1 knockdown and overexpression on TWIST1 and E-
cadherin expression. CCR2-H SUM225 cells expressing control shRNAs or shRNAs to 
ALDH1A1 wee cultured in 3D Matrigel: Collagen for 10 days, and were analyzed for 
expression of A. E-cadherin and B. TWIST1 by immunofluorescence staining. CCR2-KO 
DCIS.com cells expressing pHAGE control or ALDH1A1 were cultured in 3D Matrigel: 
Collagen for 10 days, and were analyzed for expression of C. E-cadherin and D. TWIST1 
expression. Expression was quantified by Image J, and normalized to DAPI. Statistical 
analysis was performed using One Way ANOVA with Bonferroni post-hoc comparison (A,B) 
or Two Tailed T-test (C,D). Statistical significance was determined by p<0.05. Statistical 
significance was determined by p<0.05. n.s=not significant. Mean+SEM are shown.



















































Figure S8.  Effect of HTRA2 overexpression in 
SUM225 CCR2-H cells on transwell invasion. SUM225 
CCR2-H cells stably expressing pHAGE vehicle control or 
overexpressing HTRA2 were analyzed for transwell 
invasion. Statistical analysis was performed using Two 
Tailed T-test. Statistical significance was determined by 
p<0.05. *p<0.05. Mean+SEM are shown.




























































































































Figure S9. Effect of HTRA2 overexpression and knockdown on TWIST1 and 
E-cadherin expression. CCR2-H SUM225 cells expressing pHAGE control or 
HTRA2 were cultured in 3D Matrigel: Collagen for 10 days, and were analyzed for 
expression of A. TWIST1 and B. E-cadherin expression. CCR2-KO DCIS.com cells 
expressing control shRNAs or shRNAs to HTRA2 wee cultured in 3D Matrigel: 
Collagen for 10 days, and were analyzed for expression of C. TWIST1 and D. E-
cadherin by immunofluorescence staining. Expression was quantified by Image J, 
and normalized to DAPI. Statistical analysis was performed using Two Tailed T-test 
(A,B) or One Way ANOVA with Bonferroni post-hoc comparison (C,D). Statistical 
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